{
    "nctId": "NCT03983382",
    "briefTitle": "A Study of Limited Heart Monitoring During Non-anthracycline Trastuzumab-based Therapy in Breast Cancer Patients",
    "officialTitle": "A Safety and Feasibility Study of Limited Cardiac Monitoring During Non-anthracycline Trastuzumab-based Therapy in Patients With HER2-positive Breast Cancer",
    "overallStatus": "ACTIVE_NOT_RECRUITING",
    "conditions": "Breast Cancer",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 194,
    "primaryOutcomeMeasure": "Frequency of cardiac adverse events, defined by a compositive of clinical heart failure (NYHA class III or IV) or cardiac death.",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Age \\>/= 18 years\n* Newly diagnosed histologically confirmed primary invasive breast carcinoma (Stage I-IV)\n* Pathologically confirmed HER2-positive breast cancer\n* Planned to receive trastuzumab-based therapy for a minimum of 12 months, or started trastuzumab-based therapy within the last weeks with a planned duration of at least 12 months.\n* Normal LV systolic function (EF greater than or equal to the institutional lower limit of normal)\n* William and able to comply with the requirements of the protocol\n\nExclusion Criteria:\n\n* Planned to receive an anthracycline-based regimen\n* Prior history of treatment with anthracycline chemotherapy\n* History of cardiovascular including cardiomyopathy, heart failure, or any other clinically significant cardiovascular disease (as determined by the investigator)\n* Uncontrolled hypertension, defined as systolic blood pressure \\>/= 160 mmHg and/or diastolic blood pressure \\>/= 90 mmHg (as determined by the investigator)",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}